Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Pirfenidone (PFD)
DRUG
4 trials
Sponsors
Michael Roth
, Ziauddin University
, PureTech
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interstitial Lung Disease
Oral Submucous Fibrosis
Pharmacokinetic Analysis
Scleroderma, Systemic
Phase 1
Fibrosis-Modulating Effects of Metformin and Pirfenidone in Oral Submucous Fibrosis
Completed
NCT06871904
Ziauddin University
Oral Submucous Fibrosis
Start: 2025-04-07
End: 2025-12-30
Updated: 2026-02-03
PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects
Completed
NCT07456800
PureTech
Pharmacokinetic Analysis
Start: 2021-07-12
End: 2022-01-20
Updated: 2026-03-06
Phase 2
Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
Completed
NCT03221257
Michael Roth
Interstitial Lung Disease, Scleroderma, Systemic
Start: 2017-11-28
End: 2022-06-13
Updated: 2023-12-15
Phase 3
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
NCT07284602
PureTech
Idiopathic Pulmonary Fibrosis (IPF)
Start: 2026-06-26
End: 2029-12-01
Target: 1100
Updated: 2026-09-03
Related Papers
Oral Submucous Fibrosis in 2025: An Updated Narrative on Molecular Pathogenesis, Salivary Biomarkers, and Emerging Therapeutics
Zenodo (CERN European Organization for Nuclear Research)
2026-06-11
Oral Submucous Fibrosis in 2025: An Updated Narrative on Molecular Pathogenesis, Salivary Biomarkers, and Emerging Therapeutics
Zenodo (CERN European Organization for Nuclear Research)
2026-06-11